drug

MT-2990

Phase 2updated 5mo ago

by Tanabe Pharma Corp

Phase 2

community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying MT-2990

phase1An Exploratory Study of MT-2990 in Patients With AAVcompletedn=5
phase2Safety and Efficacy Study of MT-2990 in Women With Endometriosiscompletedn=76
phase1A Clinical Pharmacology Study of MT-2990 in Seasonal Allergic Rhinitis Patientscompletedn=75

News(1)

Tolerance continues thymus-focused deals with $560M pact for Tanabe's clinical-stage IL-33 drug
After vaulting into the clinic by licensing a fusion protein last month, Tolerance Bio has continued to strengthen its thymus-focused pipeline by picking up an anti-IL-33 drug from Tanabe Pharma.
fiercebiotech · 3d ago

Data sources

ClinicalTrials.gov

last refreshed 34m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug

save

MT-2990

Phase 2updated 5mo ago

by Tanabe Pharma Corp

Phase 2

community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying MT-2990

phase1An Exploratory Study of MT-2990 in Patients With AAVcompletedn=5
phase2Safety and Efficacy Study of MT-2990 in Women With Endometriosiscompletedn=76
phase1A Clinical Pharmacology Study of MT-2990 in Seasonal Allergic Rhinitis Patientscompletedn=75

News(1)

Tolerance continues thymus-focused deals with $560M pact for Tanabe's clinical-stage IL-33 drug
After vaulting into the clinic by licensing a fusion protein last month, Tolerance Bio has continued to strengthen its thymus-focused pipeline by picking up an anti-IL-33 drug from Tanabe Pharma.
fiercebiotech · 3d ago

Data sources

ClinicalTrials.gov

last refreshed 34m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

MT-2990

all catalysts(0)

Trials studying MT-2990

News(1)

Report a data issue

comments(0)

MT-2990

all catalysts(0)

Trials studying MT-2990

News(1)

Report a data issue

comments(0)